Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells

Background aimsCurrently available treatment methods for advanced plasmacytoma include surgery, chemotherapy, radiotherapy, immunomodulatory agents, hematopoietic stem cell transplantation and donor lymphocyte infusion. We report a case of advanced refractory multiple solitary plasmacytomas in a 68-year-old Asian man with multiple bone lesions, in whom autologous cytokine-induced killer (CIK) cells were administered in an effort to eliminate residual tumor lesions.MethodsCIK cells were infused monthly for 21 courses.ResultsThe patient has survived 63 months since the first hospital visit without disease progression for 40 months.ConclusionsThis case represents the first report of autologous CIK cell immunotherapy used successfully to suppress multiple solitary plasmacytomas and resolve bone lesions.